


REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP03/04180 into the U.S. National Phase of prosecution. An Abstract on a separate sheet is attached as required under 37 CFR 1.72(b). Claims 3 to 21 have been amended to remove multiple dependencies. Entry of this amendment into the record is requested.

Respectfully submitted,




Soma G. Simon
Attorney for Applicants
Registration No. 37,444

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5019
Facsimile (610) 270-5090
n:\soma\cases\p33037\prelim.doc

ABSTRACT OF THE DISCLOSURE

Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed:



wherein R_1 is hydrogen, hydroxy, fluoro, chloro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy or halo C_{1-6} alkoxy; m is 0 when --- is a double bond and m is 1 when --- is a single bond; R_2 is hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is $-(CH_2-CH_2)-$, $-(CH=CH)-$, $-(CH_2)_3-$, $-C(CH_3)_2-$, $-(CH=CH-CH_2)-$, $-(CH_2-CH=CH)-$ or a group $-(CHR_5)-$ wherein R_5 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy or C_{1-6} alkylthio; R_3 is halogen, cyano, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy, C_{1-6} alkylthio, hydroxy, amino, mono- or di- C_{1-6} alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, aryl, aryl C_{1-6} alkyl, aryl C_{1-6} alkyloxy, aryl C_{1-6} alkylthio or $COOR_6$, $CONR_7R_8$ or COR_9 wherein R_6 , R_7 , R_8 and R_9 are independently hydrogen or C_{1-6} alkyl; p is 0, 1 or 2 or 3; R_4 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6} alkanoyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, $-CH_2-$ or NR_{10} wherein R_{10} is hydrogen or C_{1-6} alkyl; D is a single bond, $-CH_2-$, $-(CH_2)_2-$ or $-CH=CH-$; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is $-NR_{11}R_{12}$ where R_{11} and R_{12} are independently hydrogen or C_{1-6} alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.